Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Multivalent GBS Vaccine in Women and Infants
NCT03765073Phase 2Completed
- Sponsor
- Pfizer
- Start
- Jan 2019
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of ritlecitinib tosilate in group B streptococcal infection, sponsored by Pfizer. Started Jan 2019; status: completed.
02
Drugs
ritlecitinib tosilate
03
Conditions
group B streptococcal infection
Beyond the preview
Go deeper on NCT03765073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03765073.